These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781 [TBL] [Abstract][Full Text] [Related]
30. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. Arbeit JM; Olson DC; Hanahan D Oncogene; 1996 Nov; 13(9):1847-57. PubMed ID: 8934530 [TBL] [Abstract][Full Text] [Related]
31. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test. Rogala E; Skopińska-Rózewska E; Sommer E; Pastewka K; Chorostowska-Wynimko J; Sokolnicka I; Kazoń M Anticancer Res; 2001; 21(6B):4259-63. PubMed ID: 11908679 [TBL] [Abstract][Full Text] [Related]
32. Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells. Billottet C; Elkhatib N; Thiery JP; Jouanneau J Mol Biol Cell; 2004 Oct; 15(10):4725-34. PubMed ID: 15282342 [TBL] [Abstract][Full Text] [Related]
33. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. Kim MH J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886 [TBL] [Abstract][Full Text] [Related]
34. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704 [TBL] [Abstract][Full Text] [Related]
35. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Balbay MD; Pettaway CA; Kuniyasu H; Inoue K; Ramirez E; Li E; Fidler IJ; Dinney CP Clin Cancer Res; 1999 Apr; 5(4):783-9. PubMed ID: 10213213 [TBL] [Abstract][Full Text] [Related]
36. Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells. Feng S; Wang F; Matsubara A; Kan M; McKeehan WL Cancer Res; 1997 Dec; 57(23):5369-78. PubMed ID: 9393762 [TBL] [Abstract][Full Text] [Related]
37. The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Nguyen M; Lee MC; Wang JL; Tomlinson JS; Shao ZM; Alpaugh ML; Barsky SH Oncogene; 2000 Jul; 19(31):3449-59. PubMed ID: 10918603 [TBL] [Abstract][Full Text] [Related]
38. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Graeven U; Rodeck U; Karpinski S; Jost M; Philippou S; Schmiegel W Cancer Res; 2001 Oct; 61(19):7282-90. PubMed ID: 11585767 [TBL] [Abstract][Full Text] [Related]
39. Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases. Yayon A; Ma YS; Safran M; Klagsbrun M; Halaban R Oncogene; 1997 Jun; 14(25):2999-3009. PubMed ID: 9223663 [TBL] [Abstract][Full Text] [Related]
40. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Min HY; Doyle LV; Vitt CR; Zandonella CL; Stratton-Thomas JR; Shuman MA; Rosenberg S Cancer Res; 1996 May; 56(10):2428-33. PubMed ID: 8625323 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]